secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2022-11-25T23:59:59+00:00
Accession:  0001213900-22-075030
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences receives Nasdaq delisting notice; trading to be suspended Dec 2, 2022
--------------------------------------------------------------------------------

- Received second Nasdaq deficiency letter on Nov 23, 2022 for failing $2.5M stockholders' equity requirement.
- As of Sept 30, 2022, stockholders' equity was $2,227,768, below the minimum.
- Trading suspension scheduled for Dec 2, 2022 unless appeal is filed.
- Company intends to request hearing before an independent panel to stay suspension.
- No immediate effect on trading of units, common stock or warrants under REVBU, REVB, REVBW.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/ea169284-8k_revelation.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-075030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer